From Rare to Common Disorders:
Maximise on the Opportunity in CNS Gene Therapies
Focusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation, Gene Therapy for Neurological Disorders Europe is not one to miss as you seek to accelerate the development of your neurological gene therapy.
Discover the latest neurological targets, familiarise yourself with the European landscape, and debate and discuss with the leading minds of the field from the likes of UCB, Lysogene, UniQure and AskBio, as they seek to harness the opportunity and move from rare to common disorders such as Alzheimer’s, Parkinson’s and epilepsy.
Past Attendees Have Said:
Shephard Mpofu, Senior Vice President & Chief Medical Officer, Novartis Gene Therapies
Michael Fossel, President, Telocyte
"A great opportunity for learning from other industry experts.”
Marie-Laure Nevoret, Senior Lead - Clinical Development, REGENXBIO